Immunosuppression under Trial: Proceedings of the 31st Conference on Transplantation and Clinical Immunology, 3–4 June, 1999

Front Matter....Pages i-ix
Front Matter....Pages 1-1
Current results as reference for future improvements in immunosuppression....Pages 3-9
Rationale of clinical trials from the physician....Pages 11-13
Minimal standards for reporting clinical trial results in transplantation....Pages 15-24
Methodological approach of clinical trials for renal transplantation....Pages 25-37
Front Matter....Pages 39-39
Surrogate end-points for clinical trials in renal transplantation....Pages 41-51
Is acute rejection an appropriate surrogate marker for clinical trials in liver transplantation?....Pages 53-56
The success of clinical immunosuppressive trials in heart transplantation: the early detection of acute rejection....Pages 57-59
Front Matter....Pages 61-61
Factors influencing long-term allograft survival....Pages 63-65
Front Matter....Pages 67-67
Patients’ appraisal of side effects in quality of life assessments of immunosuppressive regimens....Pages 69-80
Cardiovascular complications after renal transplantation....Pages 81-88
Strategies to minimize nephrotoxicity associated to calcineurin inhibitors....Pages 89-99
Diabetogenic effect of immunosuppressive drugs....Pages 101-103
Can we minimize long-term side effects of immunosuppressive drugs on lipid metabolism?....Pages 105-109
Can we minimize the long-term side effects of immunosuppressive drugs in pediatric patients?....Pages 111-121
Front Matter....Pages 123-123
Induction therapy....Pages 125-129
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens....Pages 131-144
Immunosuppression in composite tissue transplantation....Pages 145-151
The search for immunosuppressive synergy....Pages 153-155
Economic analysis of immunosuppression in transplantation: a review of recent studies in liver and kidney transplantation....Pages 157-166
Front Matter....Pages 167-167
Questions raised by the exclusion of ‘at risk’ conditions from current trials in organ transplantation....Pages 169-178
Back Matter....Pages 179-179